Metrics
189,636 Downloads
Contact Share
heiDATA is an institutional repository for Open Research Data from Heidelberg University. It is managed by Heidelberg University's Research Data Unit, a joint institution of the University Library and the Computing Centre. If you are interested in publishing your data here, please have a look at our user guide and get in touch with us. Detailed information on heiDATA can be found in our service description.
Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Advanced Search

2,931 to 2,940 of 9,047 Results
Vardarli_Suppl Fig 34.pdf
Vardarli_Suppl Fig 34.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 70.6 KB - MD5: 443bc4569f1231d2a43fc5d8673c139d
Suppl. Fig. 34. Galbraith plot for trials investigating hypophysitis/hypopituitarism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 35.pdf
Vardarli_Suppl Fig 35.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 64.1 KB - MD5: ba984fd679c86b272e1d13f3d8ad2365
Suppl. Fig. 35. Funnel plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 36.pdf
Vardarli_Suppl Fig 36.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 66.8 KB - MD5: 556e803b091dfed445b705972e835632
Suppl. Fig. 36. Funnel plot for subgroups of ICI types trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 37.pdf
Vardarli_Suppl Fig 37.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 64.0 KB - MD5: de822d4b8ef9cacb467052fdc63730d2
Suppl. Fig. 37. Funnel plot with trim-and-fill for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 38.pdf
Vardarli_Suppl Fig 38.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 71.3 KB - MD5: 1dd5eec104223934185b7fef6e56cc4d
Suppl. Fig. 38. Galbraith plot for trials investigating hypophysitis/hypopituitarism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 39.pdf
Vardarli_Suppl Fig 39.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 64.4 KB - MD5: 5bf15c23af6441a53ca79acff68d604c
Suppl. Fig. 39. Funnel plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 3.pdf
Vardarli_Suppl Fig 3.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 81.2 KB - MD5: 5d7d92c2e8572e1ec23068a2ed383898
Suppl. Fig. 3. Forest plot for leave-one out meta-analysis for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 40.pdf
Vardarli_Suppl Fig 40.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 67.1 KB - MD5: 23a3912a62f8977ad3197d69d3b0cd41
Suppl. Fig. 40. Funnel plot for subgroups of ICI types trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 41.pdf
Vardarli_Suppl Fig 41.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 64.2 KB - MD5: ad6c63c17fd489fa8c647b90891930e3
Suppl. Fig. 41. Funnel plot with trim-and-fill for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 42.pdf
Vardarli_Suppl Fig 42.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 70.1 KB - MD5: b5a0ac42aea01ae65c1000f3ad49c2b0
Suppl. Fig. 42. Galbraith plot for trials investigating adrenal insufficiency any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Add Data

Sign up or log in to create a dataverse or add a dataset.

Sign Up Log In
Share Dataverse

Share this dataverse on your favorite social media networks.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.